The Joint Corp. · NASDAQ:JYNT
The Joint — JOINT — Q3 2026 Earnings Presentation
23 slides from The Joint's earnings presentation, Nov 5, 2026
Slide 1: Q3 2026 Financial Results
1NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q3 2026 Financial Results As of September 30, 2026, reported on November 5, 2026
Slide 2: Forward-Looking Statements
2NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financ
Slide 3: Sanjiv Razdan, CEO, President and Director
3NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Sanjiv Razdan CEO, President and Director
Slide 4: A Capital-light, Pure-play Franchisor
4NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | A Capital-light, Pure-play Franchisor Strengthened patient engagement and our reshaped operating model helped drive revenue growth and stronger profitability from continuing operations o Growing active membership count and patient retenti
Slide 5: Q3 2026 Year-over-Year Improvements
5NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q3 2026 Year-over-Year Improvements Adjusted EBITDA From Continuing Operations +$0.9M $2.3M$13.6M Total Revenue +1% $1.5M Net Income from Continuing Operations +$1.2M
Slide 6: Membership & Patient Metrics
6NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Membership & Patient Metrics • Improved conversion and retention supported active membership count quarter-over-quarter • Gains in lifetime value by increased number of months per active member, and total dollars per active member • Lower
Slide 7: Three Growth Pillars
7NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Three Growth Pillars Strategies To Improve Comp Sales: • Strengthen patient acquisition with AI-powered lead management and digital visibility efforts • Improve conversion and retention with flexible plans and personalized engagement • Wi
Slide 8: Expanding Our Clinic Network
8NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Strategies: • Improve new clinic economics, with 2026 openings reaching breakeven in ~3 months versus 18 months historically • Attract well-capitalized, experienced multi-unit franchisees, support existing franchisee expansion, and broade
Slide 9: Growing Interest in Longevity & Healthspan
9NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Growing Interest in Longevity & Healthspan Strategies: • Use consumer research to personalize the patient experience, emphasizing pain relief, improved mobility and longer-term engagement • Test proprietary clinical care protocols with me
Slide 10: Refranchising Efforts
10NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Refranchising Efforts • Once the 15 remaining lease assignments are completed, there will be no remaining company-owned or managed clinics • Benefits of the model are increasingly visible in results • Growth initiatives have better posit
Slide 11: Scott Bowman, Chief Financial Officer
11NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Scott Bowman Chief Financial Officer
Slide 12: Operating Metrics
12NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | • $123.3M Q3 2026 System-wide Sales1 (3.1)% vs Q3 2025 • (1.9)% Q3 2026 Comp Sales2 90 basis-point improvement vs Q2 2026 • $3.3M Q3 2026 Consolidated Adjusted EBITDA In line with Q3 2025 1 System-wide sales include revenues at all clini
Slide 13: Third Quarter Results
13NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Third Quarter Results $ in Millions 1 3 months ended 09/30/26 3 months ended 09/30/25 Difference Revenue $13.6 $13.4 +$0.2 Cost of revenues $2.4 $2.7 ($0.3) Selling and marketing expenses $2.7 $2.8 ($0.1) Depreciation and amortization $0
Slide 14: Strong Balance Sheet
14NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Strong Balance Sheet $ in Millions 09/30/26 06/30/26 Unrestricted cash $18.3 $22.2 Restricted cash $1.5 $1.7 Availability on $20M JP Morgan Chase LOC $20.0 $20.0 Provides flexibility to execute our capital allocation framework, while mai
Slide 15: Capital Allocation
15NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | • Balancing system-wide growth, RD territory buybacks and stock repurchases • Improved economics and franchisee support through five RD territory buybacks year-to-date • Returned capital opportunistically; repurchased ~461,000 shares for
Slide 16: Clinic Portfolio
16NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 12 26 82 175 242 265 309 352 394 453 515 610 712 800 842 885 915 4 47 61 47 48 60 64 96 126 135 125 75 15 1 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Q3 2026 TOTAL CLINICS OPEN at quarter-end Franchi
Slide 17: A Starting Point for Higher Profitability
17NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | A Starting Point for Higher Profitability ~10% - 12% of System Sales ~83% - 85% of Revenue Asset Capex ~3% of Revenue Free Ca ~60% - 70% FCF Conversion* ~40% - 42% of Revenue Royalties & Fees Gross Margin G&A Expense Capital Spending Fre
Slide 18: Updated 2026 Financial Guidance
18NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Updated 2026 Financial Guidance 2026 Financial Guidance 2025 Low High Actual System-wide Sales 1 ($ in Millions) $508 $512 $532.4 Comp Sales 2 (%) (3.5)% (2.5)% (0.4)% Consolidated Adjusted EBITDA (Unchanged) ($ in Millions) $12.5 $13.5
Slide 19: Sanjiv Razdan, CEO, President and Director
19NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Sanjiv Razdan CEO, President and Director
Slide 20: Reigniting Growth
20NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Reigniting Growth ✓ Strengthening the foundation for long-term growth, with active membership increasing, spending per active member rising, and conversion and retention improving ✓ Building on stronger new clinic performance and positiv
Slide 21: Performance Metrics and Non-GAAP Measures
21NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Performance Metrics and Non-GAAP Measures This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the Company or by franchisees. While franchised sales are
Slide 22: Quarterly GAAP – Non-GAAP Reconciliation
22NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Quarterly GAAP – Non-GAAP Reconciliation
Slide 23: Contact
23NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Scott Bowman, CFO scott.bowman@thejoint.com The Joint Corp. 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com The Joint Corp. 16767 N. Perimeter Dr., Suite